

Expanding the Horizon for the Treatment of Solid Tumors With Antibody Drug Conjugates (ADCs)

Friday, 20 November 2020, 12:00–13:30 SGT, on channel 4

Objectives

- To update on the current treatment landscape surrounding ADCs in solid tumors
- To educate on recent innovations in ADC technology
- To share the clinical experience with ADCs in solid tumors to date

Tony Mok, MD

The Chinese University of Hong Kong, Sha Tin, Hong Kong

Hyun Cheol Chung, MD, PhD

Yonsei Cancer Center, Seoul, Korea

Rebecca Dent, MSc, MD

National Cancer Center Singapore, Singapore

Keunchil Park, MD, PhD

Samsung Medical Center at Sungkyunkwan University School of Medicine, Seoul, Korea

Agenda

Friday, 20 November 2020, 12:00–13:30 SGT

12:00–12:05	Welcome and introduction	Tony Mok
12:05–12:20	How are technologically advanced ADCs expanding the horizon for the treatment of solid tumors?	Tony Mok
12:20–12:40	Expanding the horizon for the treatment of breast cancer with ADCs	Rebecca Dent
12:40–12:55	Expanding the horizon for the treatment of lung cancer with ADCs	Keunchil Park
12:55–13:15	Expanding the horizon for the treatment of colorectal and gastric cancer with ADCs	Hyun Cheol Chung
Live Q&A discussion to be held on Friday, 20 November 2020, 13:15–13:30 SGT, on channel 4		
13:15–13:30	Live Q&A + summary and close	Tony Mok and faculty panel